摘要
目的观察二氯沙坦/氢氯噻嗪治疗原发性高血压合并高尿酸血症的疗效与安全性。方法选择178例原发性高血压合并高尿酸血症患者,随机分为对照组与观察组各89例,对照组每日服依那普利10mg,氢氯噻嗪12.5mg,观察组每日服二氯沙坦/氢氯噻嗪(每片含氯沙坦5mg和氢氯塞嗪12.5mg)1片,疗程均为8周。观察治疗前后血压、血尿酸水平的变化。结果观察组与对照组降压总有效率分别为95.5%、93.3%,差异无统计学意义(P〉0.05),观察组血尿酸水平较前明显降低(P〈0.01),而对照组血尿酸变化无统计学意义。对照组干咳的发生率较高。结论二氯沙坦/氢氯噻嗪治疗原发性高血压合并高尿酸血症患者,降压、降尿酸疗效佳且安全性好。
Objective To observe the efficacy and safety of Hyzaar on hyperuricemia patients with essential hypertension. Methods 178 patients with essential hypertension and hyperuricemia were randomly divided into control group and observation group with each of 89 cases. Patients in the control group were treated with enalapril, 10 mg qd, and hydrochlorothiazide, 12.5rag qd. Patients in the observation group were given i piece of Hyzaar tablet( 5rag losartan and 12.5mg hydrochloridc per tablet) per day for a course of 8 weeks. Blood pressure,serum uric acid level before and after the treatment were observed. Results Antihypertcnsive efficacy of the observation group and control group were 95.5 % and 93.3%, respectively ( P 〉 0.05 ). Serum uric acid level of the observation group was significantly decreased than before treatment( P 〈 0.01 ) ,while the serum uric acid of the control group showed no significant changes. The incidence of dry cough was higher in control group. Conclusion Hyzaar showed good efficacy in decreasing blood pressure and uric acid,and good safety in treating patients with primary hyperuricemia and hypertension.
出处
《中国基层医药》
CAS
2011年第8期1059-1060,共2页
Chinese Journal of Primary Medicine and Pharmacy